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ABSTRACT
Introduction
Our study examined the wait time from ready-to-
treat to radiation therapy for cohorts of breast cancer 
patients requiring adjuvant radiation therapy in 2001 
and in 2005 after the implementation of strategies to 
reduce wait times for radiation treatment. We also 
examined the overall time from diagnosis to radia-
tion treatment and whether distance from the cancer 
treatment centre or month of referral had an effect 
on wait times.
Methods
This population-based retrospective study looked at 
representative samples of women newly diagnosed 
with breast cancer in 2001 and 2005. Patients who 
required radiation treatment to the breast or chest 
wall were followed from first contact to the start of 
radiation treatment.
Results
Time from ready-to-treat to first radiation treatment 
was significantly reduced for patients in 2005 as 
compared with 2001, regardless of whether chemo-
therapy was administered before radiation treatment. 
Time from diagnosis to radiation treatment was not 
different by year for those who received radiation 
only. Time from diagnosis to chemotherapy was 
significantly longer in 2005. No effect of month of 
diagnosis on wait times was observed.
Interpretation
A significant improvement in the median wait time 
from ready-to-treat to first radiation treatment was 
noted from 2001 to 2005. This improvement may be 
attributable to measures taken to reduce such waits. 
However, we observed an increase in the median time 
from diagnosis to referral and from referral to consul-
tation with medical or radiation oncology (or both), so 
that the overall time from diagnosis to radiation treat-
ment was not different. Although specific intervals 
related to radiation treatment delivery were improved, 
the entire trajectory of breast cancer care experienced 
by patients needs to be considered.
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1.  INTRODUCTION
Lengthy wait times for radiation therapy (r t ) in 
Canada have been widespread and have received 
considerable media attention 1–3. during the peak of 
the crisis in the late 1990s, several jurisdictions, in-
cluding the province of Manitoba, resorted to sending 
patients requiring r t  to the United States to reduce 
wait times.
The Manpower and Standards of Care Committee 
of the Canadian association of radiation Oncologists 
(c a r o ) recommended in 2000 that the interval between 
referral and consultation not exceed 10 working days 
(not calendar days) and that the interval between con-
sultation and treatment also not exceed 10 working 
days 4. In 1991, few patients in Canada were treated 
within these timelines 5. In Canada, patients have 
sued over the wait time for breast cancer treatment 6. 
By 2002, the wait time for radiation in Ontario had 
increased to 7 weeks, and so in 2004, in response to the 
persistent r t  wait time problems, the Cancer Quality 
Council of Ontario issued a report recommending a 
4-point approach to reducing wait times 7.
To reduce wait times for r t  in the province of 
Manitoba, Manitoba Health and CancerCare Manitoba 
(c c m b ) took steps to increase the numbers of radiation 
therapists by negotiating a competitive labour agree-
ment. additional medical physicists and radiation on-
cologists were hired, and a major investment was made 
in new radiation planning and therapy equipment. The 
present study was conducted to document whether 
those measures had affected radiation wait times. 
Breast cancer was chosen because it is a frequently 
occurring malignancy with relatively standardized 59
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care and recorded events. Sub-analyses investigated 
whether seasonal variations in radiation wait times 
could be detected and whether wait times were a func-
tion of distance from the cancer treatment centre.
The c a r o  definitions and recommendations deal 
only with wait times or intervals occurring after re-
ferral to radiation oncology; they do not encompass 
the entire trajectory of care, including care delivered 
before referral 4. We therefore examined time inter-
vals from first contact and diagnosis through to r t  
so that any improvement in wait time for r t  could 
be examined in the context of all breast cancer care 
experienced by the patients.
Our study was approved by the University of Mani-
toba Health research Ethics Board and by the Health 
Information Privacy Committee of Manitoba Health.
2.  PATIENTS AND METHODS
2.1  Study Population
Women with stage 0 to iv breast cancer diagnosed in 
four representative months (January, June, September, 
November) in each of 2001 and 2005 were identified 
from the Manitoba Cancer registry. Of these women, 
those who also received local or locoregional adjuvant 
r t  were identified from c c m b  health records.
2.2  Administrative Data Sources
Under the Cancer act of the province of Manitoba, 
c c m b is legally mandated to collect, classify, and 
maintain accurate comprehensive information on all 
cancer cases in a population-based central cancer reg-
istry, the Manitoba Cancer Registry (m c r ). The m c r  is 
annually certified for quality by the North American 
association of Central Cancer registries. all patients 
in the m c r  have a unique cancer registry (c r ) number. 
Multiple sources are used to ensure high levels of case 
ascertainment. These include physician notifications, 
pathology and cytology reports, and hospitalization, 
mortality, and autopsy records. Information about 
definitive treatment has been captured since 1992 in 
the m c r , and all breast cancer cases from 1995 onward 
have been staged.
data obtained from the m c r  included date of di-
agnosis (determined by the date of the first pathology 
or cytology report to show carcinoma or carcinoma 
in situ of the breast); age and postal code at diagno-
sis; TNM information, summary disease stage, and 
tumour grade; and estrogen receptor, progesterone 
receptor, and human epidermal growth factor receptor   
status. Cases in the m c r  diagnosed in 2001 are coded 
using the International Classification of Diseases, 
9th Clinical Modification, (i c d -9-c m ) and are staged 
using the fifth edition of the AJCC Cancer Staging 
Manual from the american Joint Committee on 
Cancer 8. Cases diagnosed in 2005 are coded using 
the International Classification of Diseases, 10th 
Revision, Canada, (i c d -10-c a ) and are staged using 
the Collaborative Staging System.
all administrative, clinical, and radiation and 
chemotherapy treatment information is also main-
tained by c c m b  in computerized health records. a 
paper chart is still maintained for some documents, 
such as letters of referral and other reports that are 
not electronic.
Manitoba Health provides comprehensive health 
care coverage for essentially all residents of the 
province of Manitoba. Because Manitoba residents 
are not obliged to pay premiums for this coverage, 
nonparticipation in the plan is rare, and claims data are 
relatively complete for the entire population. Mani-
toba Health maintains computerized health claims 
databases for most physician services, including all 
fee-for-service claims made by physicians in the 
province of Manitoba for all persons registered with 
the system from 1970 to the present. Each medical 
claims record includes information on the claiming 
physician, the service date, and the type of service, 
which is coded using billing (tariff) codes indicated 
by Manitoba Health. The accuracy of the Manitoba 
Health administrative data has been established by the 
Manitoba Centre for Health Policy for a wide range 
of clinical disorders 9. Since 1984, every resident of 
Manitoba has been assigned a unique personal health 
identification number that can be used to link patient 
records across administrative health databases. link-
age of the m c r  and Manitoba Health medical claims 
database allows for the creation of a comprehensive 
record of a patient’s care from first contact through 
imaging, diagnosis, treatment, and follow-up. To 
protect confidentiality linkage uses scrambled 
identification numbers and anonymized versions of   
the databases.
2.3	 Wait	Time	Definitions
The Manitoba Health medical claims file uses 
separate billing codes for diagnostic and screening 
mammograms. For asymptomatic cancers detected 
during routine mammographic screening, first contact 
is defined as the date of the screening mammogram 
within 6 months preceding the date of diagnosis. If the 
patient had a diagnostic mammogram or ultrasound, 
but not a preceding screening mammogram, the date 
of first contact is the last physician or surgeon service 
date immediately preceding the date of the diagnostic 
mammogram or breast ultrasound within 6 months 
preceding the date of diagnosis. For women who had 
no mammogram or ultrasound within 6 months pre-
ceding the date of diagnosis, the date of first contact 
is the physician or surgeon service date immediately 
preceding the date of diagnosis.
Dates of first contact, first imaging (whether 
screening or diagnostic mammography or breast 
ultrasound), surgical consultation, and surgery were 
obtained from the Manitoba Health medical claims 60
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database. The date of diagnosis and date of first sur-
gery would be the same (or very close if the pathol-
ogy report took several days to process) for patients 
who had an excisional biopsy as their diagnostic 
procedure. If more than one surgical procedure was 
required, then the “first surgery” date is defined as the 
first segmental mastectomy, mastectomy, or axillary 
node dissection that occurred on or after the diagno-
sis date; the “last surgery” date is defined as the last 
segmental mastectomy, mastectomy, or axillary node 
dissection that occurred on or before the oncology 
referral date (Figure 1).
dates of referral to oncology, dates of medical 
and radiation oncology consultation, and chemo-
therapy start dates were obtained from c c m b  health 
records. The date of oncology referral is defined as 
the date on which a referral for medical or radiation 
oncology assessment (or both) was received at c c m b  
or received by a community-based medical oncolo-
gist before referral to c c m b  for radiation oncology 
consultation. referral dates for 34 patients who were 
seen by a community-based medical oncologist be-
fore being referred to c c m b  for radiation oncology 
consultation were not available. For these patients, 
a proxy referral date was assigned using the date of 
the pathology report of the last surgery before the 
community-based medical oncology consultation. 
For patients who received neoadjuvant chemo-
therapy following a diagnostic procedure, the date 
of the pathology or cytology report of the diagnostic 
procedure was used as a proxy for the referral date. 
The date of consultation was the date on which the 
first oncologist (whether medical or radiation) saw 
the patient.
Because patients who have chemotherapy first, 
followed by r t , have an interval before r t  that is not 
waiting per se, another date, “ready-to-treat” was 
defined. “Ready-to-treat” is defined as the date on 
which a decision is made by the radiation oncologist 
and the patient that r t  is indicated and that the patient 
is medically ready and willing to begin treatment. 
This definition is in keeping with the c a r o 2000 
recommendations for multimodality treatment 4. The 
ready-to-treat date was determined by the wait list co-
ordinator from c c m b  health records. For patients who 
received chemotherapy, the ready-to-treat date was 4 
weeks after the last dose of scheduled and adminis-
tered intravenous cytotoxic therapy. For patients who 
received r t  only, “ready-to-treat” would usually be 
the date of the r t  requisition, which is usually also the 
date of the radiation oncology consultation. Patients 
will occasionally ask for r t  deferrals for personal rea-
sons, which would constitute the balance of the cases, 
and in these cases, “ready-to-treat” would be defined 
as the date on which the patient returns and agrees to 
proceed. distance from the cancer treatment centre 
was determined by the postal code of the patient. 
Patients were classified as urban (within Winnipeg), 
f i g u r e  1  Comparison of 2001 and 2005 wait times for breast cancer patients along the trajectory of care. Intervals between breast cancer 
events are shown in median days, 2001 compared with 2005. For each pair of diamonds, the top diamond shows the 2001 mean elapsed days 
(25th–75th percentile), and the bottom diamond shows the 2005 median elapsed days (25th–75th percentile). Significant differences appear 
in the darker grey shade, and p values are adjusted for multiple testing. * Including mastectomy, partial mastectomy, and axillary dissection 
if carried out at separate times.61
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near-urban (within 100 km of Winnipeg), and rural 
(more than 100 km from Winnipeg).
Sequential and exclusive time intervals and com-
posite time intervals measured in elapsed calendar 
days were calculated as indicated in Figure 1.
2.4  Statistical Analyses
The distribution of a time interval may show skew 
in this type of analysis. For that reason, compari-
sons used the median two-sample test (two-sided). 
Corrections were made for multiple testing, where 
appropriate. all tabulations and statistical analyses 
were performed using SAS version 9.1 (SAS Institute, 
Cary, NC, U.S.A.).
3.  RESULTS
From the m c r , we identified 641 cases of breast car-
cinoma that were diagnosed in the months of interest 
in 2001 and 2005. Three cases with diagnoses of sar-
coma, leiomyosarcoma, and phyllodes tumour were 
removed from the study. radiation treatment to the 
breast or chest wall was prescribed in 332 cases (330 
patients, 2 with bilateral breast cancer). The patients 
in those cases are the subjects of the present study.
Table i shows the patient tumour and treatment 
characteristics by year, together with chi-square test 
results to determine whether those characteristics 
varied by year of diagnosis. Only patients who re-
ceived r t with or without chemotherapy or hormonal 
therapy (or both) are included. The increase in newly 
diagnosed patients from 2001 to 2005 (156 vs. 176) is 
consistent with the expected 2%–3% annual increase 
in the province of Manitoba 10. No significant differ-
ences were seen between the 2001 and 2005 cohorts, 
with the exception of an increased use of sentinel node 
biopsy in 2005. A small, nonsignificant, increase in 
accelerated hypofractionated whole-breast radiation 
is noted. No effect of month of referral on wait times 
could be detected. all patients in a given year were 
pooled for further analysis.
Figure 1 outlines the flow of patients through 
breast cancer care events from first contact to the 
beginning of r t. A large and significant improvement 
in the median wait time from ready-to-treat to r t  was 
noted regardless of whether chemotherapy was given 
before r t . For those who received chemotherapy, the 
median time from ready-to-treat to r t  was reduced 
to 8 days from 20 days (p < 0.0001). For those not 
receiving chemotherapy, the median time from ready-
to-treat to r t  was reduced to 23.5 days from 44 days 
(p < 0.0001). In both 2001 and 2005, patients who 
received chemotherapy tended to have a lesser wait 
time for r t  after ready-to-treat than did patients who 
did not receive chemotherapy.
Because the first contact date is derived using 
an algorithm based on administrative data and may 
include a proxy date, it is considered less certain, and 
we have used date of diagnosis as a starting point for 
our composite intervals. The care path splits into those 
who did and who did not receive chemotherapy. For 
patients who received chemotherapy first, the me-
dian wait time from diagnosis to first chemotherapy   
significantly increased to 98 days from 76 days   
(p = 0.0012). However, median wait time from 
medical oncology consult to first chemotherapy did 
not increase significantly (14 days vs. 18.5 days, p = 
0.16), suggesting that the wait time from diagnosis 
to chemotherapy was increased by events before the 
medical oncology consultation. The time waited by 
patients from referral to oncology consultation also 
showed a slight but significant increase for the wait 
to see a medical or radiation oncologist to 21.5 days 
from 18.0 days (p = 0.001).
Overall, the median wait time from diagnosis to 
r t for those receiving radiation only was not different 
from 2001 to 2005 at 129.5 days compared with 125 
median days respectively (p = 0.55).
The time from diagnosis to first surgery was 
significantly increased for the 2005 cohort, at 22 
days compared with 35 days (p = 0.0003), as was the 
time from surgical consult to first surgery, 15 days 
compared with 20 days (p = 0.0022, data not shown). 
The median wait time from diagnosis to oncology 
referral, which is a composite measure of all activi-
ties leading up to referral, including additional imag-
ing, surgical consultation, surgery or surgeries, and 
pathology turnaround times significantly increased 
from 2001 to 2005, at 42.5 days compared with 53 
days (p = 0.0025).
Distance from the cancer centre as identified 
using postal code at diagnosis was examined to de-
termine if a correlation with wait time intervals was 
evident (Table ii). A significant difference in median 
wait time from diagnosis to referral was observed for 
the three distance categories in 2001 (p = 0.0093), 
but no difference was found in 2005. Median wait 
time from ready-to-treat to r t  was not affected by 
distance from the cancer centre in either year (data 
not shown).
4.  DISCUSSION
In this study of patients receiving breast or chest wall 
r t  for newly diagnosed breast cancer at c c m b , the 
median wait time from ready-to-treat to r t  signifi-
cantly improved from 2001 to 2005. a decrease of 
16 days for patients receiving chemotherapy first and 
a decrease of 20.5 days for those receiving r t  alone 
were observed, suggesting that the investments made 
by Manitoba Health and c c m b  in staffing, treatment 
hardware, and planning software were successful in 
reducing wait times for r t . However, no improvement 
in the overall median time from diagnosis to r t  was 
observed for those receiving radiation only.
A significant worsening in the time from diag-
nosis to chemotherapy was noted, but no significant 62
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t a b l e  i  Comparison of the 2001 and 2005 cohorts
  Characteristic  2001  2005  p
   (n)  (%)  (n)  (%)  Valuea
Patients  156    176    —
diagnosis month         
  Jan  47  30.1  47  26.7  n s
  Jun  33  21.2  45  25.6 
  Sep  36  23.1  38  21.6 
  Nov  40  25.6  46  26.1 
Stage        
  0  20  12.8  28  15.91  n s
  i  69  44.2  74  42.05 
  ii  54  34.6  48  27.27 
  iii/iv  13  8.3  26  14.77 
Grade         
  i  30  19.2  34  19.32  n s
  ii  75  48.1  78  44.32 
  iii  42  26.9  53  30.11 
  Unknown  9  5.8  11  6.25 
age at diagnosis         
     49 years  43  27.56  31  17.61  n s
  50–69 years  78  50  114  64.77 
     70 years  35  22.44  31  17.61 
Type of surgery         
  lumpectomy  127  82.5  134  77  n s
  Mastectomy  27  17.5  40  23 
Sentinel node biopsy         
  Yes  18  11.5  102  58  <0.0001
  No  138  88.5  74  42 
Nodal status         
  Positive  54  39.1  55  37.2  n s
  Negative  74  53.6  86  58.1 
  Unknown  10  7.2  7  4.7 
Estrogen receptor status         
  Positive  113  72.4  132  75  n s
  Negative  37  23.7  39  22.2 
  Unknown  6  3.8  5  2.8 
Progesterone receptor status         
  Positive  95  60.9  120  68.2  n s
  Negative  54  34.6  51  29 
  Unknown  7  4.5  5  2.8 
Chemotherapy         
  Yes  73  46.8  76  43.2  n s
  No  83  53.2  100  56.8 
radiation therapy         
  4000–4999 cGy  36  23.2  50  28.9  n s
  5000+ cGy  119  76.8  123  71.1 
a  By chi-square test with Bonferroni correction.63
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difference in the wait time from medical oncology 
consultation to chemotherapy was seen, suggesting 
that the increased overall time to chemotherapy was 
a result of events before consultation.
In both years, the time from ready-to-treat to r t  
was shorter for patients who received chemotherapy 
before r t  than for those who did not. This finding 
likely reflects the advance notice given to the r t  pro-
gram for patients receiving chemotherapy first; it is 
consistent with work in Quebec, which demonstrated 
that delays to r t  are more prevalent among patients 
who do not receive chemotherapy before radiation, 
and with data from Ontario, which showed that pa-
tients who did not receive chemotherapy experienced 
the longest waits for r t  11,12.
In the present study, improvement in the timeli-
ness of r t  delivery for those who were treated with 
r t  only was negated by a worsening of the median 
times from diagnosis to surgery and from referral to 
oncology consultation such that the overall elapsed 
time experienced by the patients remained the same. 
This finding suggests that the entire care experience of 
patients needs to be considered and that an improve-
ment in one wait list that is only a part of a sequence 
of wait lists does not necessarily result in an overall 
benefit, an observation that is consistent with research 
from Nova Scotia that demonstrated the importance 
of evaluating time intervals along the entire trajectory 
of care so as to better understand the location and 
magnitude of changes in wait times 13,14.
despite major improvements by 2005, neither 
the 75th percentile nor the median wait time from 
ready-to-treat to r t met c a r o guidelines 4 except 
for patients who needed chemotherapy first. Recent 
experience at c c m b in 2008 indicates considerable 
further improvement since 2005 in r t wait times, 
which are now approaching c a r o  recommendations 
(CancerCare Manitoba. Month End Wait List Sum-
mary. Internal communication).
The worsening of the median wait time before 
oncology referral appears mostly to be a result of time 
from diagnosis to first surgery. This interval is a com-
posite of the turnaround time of the biopsy report; the 
availability of a breast cancer surgeon, anesthetist, and 
operating room time or hospital bed availability for 
patients who require an inpatient recovery period; and 
the speed with which participants in the system respond. 
Using administrative data, this study cannot address the 
contribution of each of these subintervals in individual 
patients. although the intervals cannot be directly com-
pared because of differences in methodology, an overall 
worsening of the time intervals before radiation or medi-
cal oncology referral was similarly reported in Nova 
Scotia, where it was shown that the intervals comprising 
biopsy-to-surgery and surgery-to-referral both experi-
enced prolongation between two cohorts (1999–2000 
vs. 2003–2004) 13. In the present study, the increase in 
time from referral to consultation also contributed to the 
overall wait time and did not meet c a r o  guidelines 4 in 
either year. Some of the delay was a result of long wait 
lists for medical oncology consultation experienced at 
c c m b  during the years of the study.
We did not analyze all cases diagnosed in 2001 
and 2005. The months sampled deliberately included 
times of the year during which wait times might be 
expected to fluctuate. Our data did not reveal any ef-
fect of month of diagnosis on wait times.
In a large jurisdiction such as Manitoba, there 
is concern that rural patients may be disadvantaged 
in access to care. In 2001, differences for wait times 
from diagnosis to referral were noted for the three 
geographic patient groups (Table ii). By 2005, how-
ever, there was no evidence that any patient group 
had any advantage in wait times.
The oncologic consequences of delays in com-
mencing adjuvant radiation treatment post lumpectomy 
have been examined. In a study conducted across Que-
bec, breast cancer patients who waited more than 12 
weeks after surgery for r t  had a higher rate of local fail-
ure (hazard ratio: 1.75; 95% confidence interval: 1.00 
to 3.08) after multivariate adjustment, including the 
effect of systemic therapy 15. No difference in survival 
was observed. In a single-institution study, also from 
Quebec, the time to breast r t  was associated with an 
increase in local recurrence in univariate analysis, but 
the effect became equivocal in multivariate analysis 16. 
A study conducted in Ontario could not find an effect 
of time to r t  on local control in a stepwise multivariate 
Cox regression model 17,18. Theoretic models of tumour 
control probability predict that delays in initiating 
treatment will have an adverse effect on local control, 
especially for rapidly growing tumours 19.
regardless of the oncologic effect of a delay in 
initiating breast r t, there are psychological and social 
t a b l e  ii  Wait time from diagnosis to referral by year and postal code of residence
  Postal code  Patients (n)  Median days
    2001  2005  (25th–75th percentile)
        2001  2005
  Urban  109  117  37 (20–54)  53 (37–74)
  Near-urban  24  30  49 (35–64.5)  52.5 (32–680)
  Rural  23  29  64 (40–72)  55 (31–76)
  p Valuea      0.0093  n s
a  By chi-square test.64
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consequences for patients, families, and treating pro-
fessionals who must manage a r t  wait list 20,21.
5.  CONCLUSIONS
Investments by Manitoba Health and c c m b  in staff-
ing, treatment hardware, and planning software were 
associated with significant reductions in median wait 
times for breast r t  from 2001 to 2005 as measured 
from ready-to-treat to commencement of r t , but still 
did not meet c a r o  guidelines. Gains in r t  wait times 
between 2001 and 2005 for those receiving radiation 
alone were equal in magnitude to increases in wait 
times that developed elsewhere in the sequence of 
care steps, so that the overall time from diagnosis to 
r t  was not significantly improved. The entire trajec-
tory of patient care needs to be considered and not 
just the time spent on the r t  wait list.
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